ISRCTN82391603
Completed
N/A
Cardiovascular effects of empagliflozin in diabetes mellitus
niversity of Leeds0 sites36 target enrollmentOctober 16, 2018
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Circulatory System
- Sponsor
- niversity of Leeds
- Enrollment
- 36
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
2021 Protocol article in https://pubmed.ncbi.nlm.nih.gov/34182806/ (added 13/08/2021)
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Type 2 diabetes mellitus
- •2\. Metformin as single or dual therapy
- •3\. Recent heart attack (\<12 months)
- •4\. HbA1c \>48mmol/ml
- •5\. 18\-84 years old
- •6\. Ability to provide informed consent
Exclusion Criteria
- •1\. Previous coronary artery bypass grafting (CABG)
- •2\. Need for further revascularisation
- •3\. Contra\-indication to CMR scanning (some pacemakers, intraorbital debris, intraauricular implants, intracranial clips etc)
- •4\. Contra\-indication to Adenosine
- •5\. Known allergy to contrast medium (gadolinium)
- •6\. Renal dysfunction with eGFR\< 60
- •7\. Obesity where girth exceeds the scanner bore
- •8\. Pregnancy or breastfeeding
- •9\. Inability to lie flat for CMR scan
Outcomes
Primary Outcomes
Not specified
Similar Trials
Unknown
Phase 4
The Effects of Empagliflozin on Arterial Wall CharacteristicsVascular StiffnessHypoglycemic AgentsDiabetes ComplicationsDiabetes Mellitus, Type 1NCT03639545University Medical Centre Ljubljana120
Not Yet Recruiting
Phase 4
Assessment of Empagliflozin effects in coronary artery diseaseIRCT20190412043247N2Zanjan University of Medical Sciences100
Completed
N/A
Effect of Empagliflozin on Endothelial Function in Cardiovascular High Risk Diabetes Mellitus: Multi-Center Placebo-Controlled Double-Blind Randomized TrialType 2 diabetes with high risk of cardiovascular diseaseJPRN-UMIN000024502Department of Cardiovascular Medicine, Saga University117
Completed
Phase 4
Effects of empagliFlozin on myocardIal metabOlic Rate of glucosE Estimated Through 18FDG PET (FIORE Study)Type 2 DiabetesCardiovascular Risk FactorNCT04183868University of Catanzaro26
Completed
Phase 4
Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)Type2 DiabetesCardiovascular DiseasesNCT02973477University of Michigan45